Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Vitamin D

The Contested Sunshine Vitamin

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

10 human trials, about 21 studies, Many RCTs + meta-analyses; conclusions still debated. The written rationale for this grade is still being prepared.

FDA
Regulated as a dietary supplement; an essential nutrient with an RDA
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Vitamin D is fat-soluble, so unlike water-soluble vitamins it can accumulate, and very high intakes can raise blood calcium to harmful levels. The doses discussed in pregnancy generally sit well within recognized limits: the IOM sets a tolerable upper intake of 4,000 IU per day for adults, and the Endocrine Society has cited higher ceilings only for specific at-risk situations. High-dose treatment regimens for deficiency have not been well studied specifically in pregnancy. People at higher risk of deficiency include those with limited sun exposure, darker skin, vegetarian or vegan diets, and higher body weight. Because screening thresholds and dosing are genuinely contested and pregnancy raises the stakes, decisions about whether to test 25-OH-D and how much to supplement should be made with an obstetric provider rather than self-directed.

Vitamin D supports calcium balance and fetal skeletal development, and severe maternal deficiency can cause congenital rickets and neonatal hypocalcemia, so correcting documented deficiency is reasonable and broadly agreed. Beyond that narrow case the evidence thins quickly, and this is one of the most contested areas in prenatal nutrition. Supplementation reliably raises blood 25-OH-D, but whether it prevents pre-eclampsia, preterm birth, low birthweight or gestational diabetes is unsettled. The 2024 Cochrane review removed about twenty earlier trials over trustworthiness concerns and rated those outcomes as low or very-low certainty. Guidelines pull in different directions: the US Institute of Medicine sets the RDA at 600 IU and sufficiency at 20 ng/mL; the 2024 Endocrine Society suggests empiric supplementation in pregnancy on low-quality evidence while advising against routine screening; ACOG declines universal screening; and WHO does not recommend routine supplementation. Any decision about testing or dose belongs with an obstetric provider.

A nutrient everyone agrees matters, where the experts genuinely disagree on how much, what blood level to aim for, and whether to screen at all.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Supporting calcium absorption and fetal bone development
  • Preventing congenital rickets and neonatal hypocalcemia in the setting of severe maternal deficiency
  • Correcting a documented maternal vitamin D deficiency identified by an obstetric provider
  • A possible but unconfirmed role in pre-eclampsia risk, still low-certainty in trials

What people get wrong

  • Often saidThere is a clear, agreed-upon vitamin D dose and blood level every pregnant person should hit.

    ActuallyThere is not. The Institute of Medicine defines sufficiency at 20 ng/mL and the older Endocrine Society position used 30 ng/mL, while the 2024 Endocrine Society guideline steps away from a specific pregnancy target and advises against routine testing altogether. ACOG declines universal screening and WHO does not recommend routine supplementation. The honest answer is that the target and the dose are genuinely unsettled.

  • Often saidVitamin D supplements clearly prevent pre-eclampsia and preterm birth.

    ActuallyThe 2024 Cochrane review is very uncertain about this. After removing about twenty earlier trials over trustworthiness concerns, it rated the effect on pre-eclampsia, preterm birth, gestational diabetes and low birthweight as low or very-low certainty, with confidence intervals that include no benefit. ACOG has said the evidence is insufficient to recommend vitamin D for preventing these outcomes.

  • Often saidCorrecting a real vitamin D deficiency is the same kind of claim as taking it to prevent pregnancy complications.

    ActuallyThese are two different claims with different evidence. Severe deficiency is linked to congenital rickets and neonatal hypocalcemia, and correcting a documented deficiency is broadly supported; supplementation reliably raises blood 25-OH-D. Using vitamin D as a general preventive against pre-eclampsia or preterm birth in women who are not deficient rests on much weaker, contested evidence.

Who profits, and who pushes back

  • The Endocrine Society

    championsSpecialty clinical guideline body

    Pregnant people benefit from a higher target of at least 30 ng/mL and intakes of roughly 1,500 to 2,000 IU per day; vitamin D deficiency in pregnancy is a serious and under-addressed concern.

  • Institute of Medicine / Food & Nutrition Board

    endorsesUS reference-intake authority

    The RDA is 600 IU per day and a blood level of at least 20 ng/mL is sufficient for bone health; this can be met by most people, with supplementation reserved for those who fall short.

  • ACOG (Committee on Obstetric Practice)

    mixedUS obstetric authority

    There is insufficient evidence to screen all pregnant women for vitamin D deficiency or to recommend supplementation to prevent preterm birth or preeclampsia; when deficiency is identified, 1,000 to 2,000 IU per day is safe.

  • World Health Organization

    cautionsGlobal antenatal-care guidelines

    Routine vitamin D supplementation is not recommended for pregnant women to improve maternal and perinatal outcomes; it should be given only where there is a documented clinical need.

Where the research comes from

Most of the published research on this comes from one place. 50% of it is from Insufficient/deficient. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
Insufficient/deficient50%
Sufficient50%

Research published from: Global.

How we got here

Rickets was described as a distinct skeletal disease in the 1650s by Glisson, Whistler and others, but the sunlight clue came from outside the clinic. In 1822 the Polish physician Jedrzej Sniadecki noted that children in smog-bound Warsaw developed rickets while rural children in the sun did not, and in 1890 Theobald Palm, comparing British industrial cities with sunnier regions abroad, argued that missing sunlight was the common thread. Rickets had by then become a disease of crowded, coal-darkened cities across Europe and North America. In 1919 Kurt Huldschinsky healed rachitic bones with ultraviolet lamps; Elmer McCollum named the antirachitic factor vitamin D in 1922; and Adolf Windaus won the 1928 Nobel Prize for the sterol chemistry behind it. Early clinicians also observed that children with darker skin needed more sun to make the same vitamin D, a fact that still shapes who is considered at higher risk in pregnancy.

  1. 1822Sniadecki links rickets in industrial Warsaw to lack of sunlight, sparing sun-exposed rural children
  2. 1890Palm's global survey ties rickets to absence of sunlight across cities and regions
  3. 1919Huldschinsky heals rachitic bones in children using ultraviolet lamp exposure
  4. 1922McCollum isolates the antirachitic factor in cod liver oil and names it vitamin D
  5. 1928Windaus receives the Nobel Prize for the sterol chemistry underlying vitamin D
  6. 2010-2011IOM sets the 600 IU RDA, 20 ng/mL sufficiency and 4000 IU upper limit; Endocrine Society argues for a 30 ng/mL target; ACOG (Opinion 495) declines universal screening
  7. 2016-2019Cochrane reviews report supplementation raises 25-OH-D and may reduce pre-eclampsia and low birthweight
  8. 2020WHO maintains that routine antenatal vitamin D supplementation is not recommended
  9. 2024Cochrane update removes ~20 trials for trustworthiness and downgrades hard outcomes to low or very-low certainty; Endocrine Society reverses toward suggesting empiric supplementation while advising against routine screening

At a glance

IOM/RDA
600 IU/day
If deficient (ACOG)
1,000-2,000 IU/day
Sufficiency (IOM)
25-OH-D ≥ 20 ng/mL
Sufficiency (Endo Soc.)
≥ 30 ng/mL

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Vitamin D. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources